Tonix Pharmaceuticals Bolsters Leadership with Experienced Executive Joseph Hand
Tonix Pharmaceuticals strengthens its executive team by appointing Joseph Hand as General Counsel and EVP of Operations, bringing extensive corporate experience ahead of a potential FDA approval for its fibromyalgia treatment.
Tonix Pharmaceuticals has appointed Joseph Hand as General Counsel and Executive Vice President of Operations, signaling a strategic move to enhance the company's leadership capabilities. Hand's extensive corporate experience, including significant roles in major pharmaceutical transactions, comes at a critical time for the company as it prepares for potential FDA approval of its fibromyalgia treatment, TNX-102 SL.
Hand brings a wealth of expertise from his previous roles, notably his involvement in high-profile corporate transactions such as Celgene's $74 billion acquisition by Bristol Myers Squibb and the $13.4 billion divestiture of Otezla® to Amgen. His appointment suggests Tonix is positioning itself for potential future strategic developments and growth.
The timing of Hand's appointment is particularly significant as Tonix prepares to submit a New Drug Application to the FDA this month for TNX-102 SL. The product candidate has already completed two statistically significant phase 3 studies for fibromyalgia management and has received Fast Track designation from the FDA.
Beyond the fibromyalgia treatment, Tonix is actively developing other innovative therapies, including a potential antiviral agent for the Department of Defense and treatments for central nervous system disorders. Hand's legal and operational expertise could prove crucial in navigating the complex pharmaceutical development and regulatory landscape.
With this strategic leadership addition, Tonix demonstrates its commitment to advancing its diverse portfolio of medical innovations and preparing for potential commercial opportunities in pain management and public health solutions.